A recent Gallup poll reveals a significant increase in the use of GLP-1 medications for weight loss among Americans. As of 2026, 11% of Americans are using these drugs, a notable rise from just 3% in 2024. This surge in usage is linked to a gradual decline in the U.S. adult obesity rate, which has decreased from a peak of 39.9% in 2022 to 36.4% in 2025
GLP-1 drugs, such as semaglutide (brands Ozempic and Wegovy), have gained popularity due to their effectiveness in promoting weight loss. According to the Gallup National Health and Well-Being Index, the increased accessibility of these medications may be contributing to the declining obesity rates. However, the diabetes diagnosis rate remains steady at 13.8%, highlighting the complexity of addressing obesity-related health issues
The poll also found that 15% of respondents have used GLP-1 medications at some point for weight loss, marking a nine percentage point increase. The growing awareness and acceptance of these drugs are evident, with nearly nine in 10 Americans now aware of their availability for weight management
Despite the positive trend in obesity rates, the impact on diabetes incidence remains unclear. Experts caution that while GLP-1 drugs support weight management, they are not a cure-all for overall health. As sustainable health improvements require a combination of medical innovation and healthier lifestyle choices
The increased use of GLP-1 medications reflects a broader shift in public health strategy, with efforts to expand access and affordability continuing. As the global GLP-1 drug market grows, driven by rising obesity rates and new drug formulations, the potential for lasting improvements in obesity management remains promising
